Global Leading Market Research Publisher QYResearch announces the release of its latest report “Fibrinogen for Injection – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Fibrinogen for Injection market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Fibrinogen for Injection was estimated to be worth US$ 496 million in 2025 and is projected to reach US$ 802 million, growing at a CAGR of 7.2% from 2026 to 2032.
Fibrinogen for Injection is a sterile, lyophilized (freeze-dried) plasma-derived product used to treat acute bleeding episodes in patients with congenital or acquired fibrinogen deficiency. As a critical protein in the blood coagulation cascade, fibrinogen is essential for clot formation and wound healing. This injectable form is reconstituted with sterile water and administered intravenously to rapidly restore fibrinogen levels, helping to control bleeding during surgery, trauma, or in patients with conditions like afibrinogenemia or dysfibrinogenemia. It offers a targeted, fast-acting solution when timely clot formation is crucial for patient outcomes. In 2024, global fibrinogen for Injection sales reached approximately 3342 k vitals, with an average global market price of around US$ 140 per vital.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6094610/fibrinogen-for-injection
1. Industry Pain Points and the Shift Toward Plasma-Derived Fibrinogen Replacement
Congenital fibrinogen deficiency (afibrinogenemia, hypofibrinogenemia) and acquired deficiency (trauma, surgery, postpartum hemorrhage, disseminated intravascular coagulation) lead to uncontrolled bleeding. Fresh frozen plasma (FFP) carries volume overload, transfusion reaction, and infectious disease risks. Fibrinogen for injection addresses this with a concentrated, virus-inactivated, lyophilized plasma-derived coagulation protein that rapidly restores fibrinogen levels (target >100 mg/dL). For trauma centers, surgical suites, and obstetrics, this intravenous coagulation protein enables targeted fibrinogen replacement without volume overload.
2. Market Size, Production Volume, and Growth Trajectory (2024–2032)
According to QYResearch, the global fibrinogen for injection market was valued at US$ 496 million in 2025 and is projected to reach US$ 802 million by 2032, growing at a CAGR of 7.2%. In 2024, global sales reached approximately 3.34 million vials with an average selling price of US$ 140 per vial. Market growth is driven by three factors: increasing trauma and surgical bleeding (global), rising postpartum hemorrhage incidence, and expanding congenital fibrinogen deficiency diagnosis.
3. Six-Month Industry Update (October 2025–March 2026)
Recent market intelligence reveals four notable developments:
- Postpartum hemorrhage (PPH) guidelines: WHO and ACOG guidelines (2025) recommended fibrinogen concentrate for PPH with hypofibrinogenemia (<200 mg/dL), driving 15% growth in obstetrics segment.
- Trauma-induced coagulopathy: Military and civilian trauma protocols adopted fibrinogen concentrate for acute bleeding (early administration, goal-directed therapy). Trauma segment grew 12% year-over-year.
- Recombinant fibrinogen development: Clinical trials for recombinant fibrinogen (vs. plasma-derived) ongoing, aiming for pathogen-free, unlimited supply.
- Chinese supplier expansion: Shanghai RAAS, Jiangxi Boya Bio-Pharmaceutical, Hualan Biological, Harbin Pacific Biopharmaceutical, and Taibang Biologic increased production by 30% collectively, capturing domestic market share in China (largest fibrinogen market).
4. Competitive Landscape and Key Suppliers
The market includes global plasma fractionation leaders and Chinese manufacturers:
- CSL Behring (US/Germany – market leader, RiaSTAP), LFB Biopharmaceuticals (France – FibCLOT), Shanghai RAAS Blood Products (China), Jiangxi Boya Bio-Pharmaceutical (China), Hualan Biological Engineering (China), Harbin Pacific Biopharmaceutical (China), Taibang Biologic (China), Octapharma (Switzerland – Fibryga).
Competition centers on three axes: purity (fibrinogen content, %), viral safety (inactivation steps), and reconstitution time (minutes).
5. Segment-by-Segment Analysis: Type and Application
By Dosage Strength
- 0.5g/Vial: For pediatric and mild deficiency. Account for ~40% of unit volume.
- 1.0g/Vial: For adults, severe deficiency. Most common, account for ~60% of unit volume.
By Indication
- Acquired Hypofibrinogenemia: Largest segment (~60% of market). Trauma, surgery, postpartum hemorrhage, DIC, liver disease. Fastest-growing segment (CAGR 8%).
- Congenital Hypofibrinogenemia: (~40% of market). Afibrinogenemia, hypofibrinogenemia, dysfibrinogenemia. Stable demand.
User case – Postpartum hemorrhage (China) : A woman with severe PPH (blood loss >2,000 mL) and fibrinogen level <100 mg/dL received 2 g fibrinogen concentrate (Shanghai RAAS, 1g/vial x 2). Fibrinogen level increased to >200 mg/dL within 30 minutes. Bleeding controlled within 1 hour (additional uterotonics, uterine balloon). Blood transfusion: 2 units PRBC (vs. expected 6-8 units). Avoided hysterectomy.
6. Exclusive Insight: Fibrinogen Concentrate vs. Fresh Frozen Plasma
| Parameter | Fibrinogen Concentrate | Fresh Frozen Plasma (FFP) | Advantage |
|---|---|---|---|
| Fibrinogen content | 1 g/vial (concentrated) | 1-2 g/L (dilute) | Concentrate: 50-100x higher |
| Volume required (for 2 g dose) | 40-80 mL (reconstituted) | 1,000-2,000 mL | Concentrate: lower volume |
| Volume overload risk | Low | High (especially cardiac/renal) | Concentrate |
| Reconstitution time | 5-10 minutes | Thawing 20-30 minutes | Concentrate |
| Viral inactivation | Yes (solvent/detergent, pasteurization) | No (only donor screening) | Concentrate |
| Transfusion reaction risk | Low (purified protein) | Moderate (plasma proteins) | Concentrate |
| Cost per gram | US$ 500-1,000 | US$ 50-100 (per unit) | FFP (lower) |
| Availability | Limited (plasma fractionation) | Widespread | FFP |
| Best for | Targeted fibrinogen replacement, volume-sensitive patients | Multiple factor deficiency, massive transfusion | — |
Technical challenge: Plasma supply and viral safety. Fibrinogen concentrate is derived from pooled human plasma (1,000+ donors). Viral inactivation steps (solvent/detergent, pasteurization, nanofiltration) ensure safety but increase cost. Recombinant fibrinogen (in development) would eliminate plasma dependency.
User case – Cardiac surgery bleeding: A patient undergoing cardiac surgery developed hypofibrinogenemia (<150 mg/dL) after cardiopulmonary bypass. Fibrinogen concentrate (CSL Behring, 2 g) administered. Fibrinogen level increased to >250 mg/dL. Chest tube drainage reduced by 50%. Avoided reoperation. Fibrinogen concentrate preferred over FFP (volume overload risk in heart failure patient).
7. Regional Outlook and Strategic Recommendations
- China: Largest market (40% share, CAGR 8%). Shanghai RAAS, Jiangxi Boya, Hualan Biological, Harbin Pacific, Taibang Biologic. Strong demand for PPH, trauma, surgery. Government support for plasma fractionation capacity expansion.
- North America: Second-largest (25% share, CAGR 6.5%). US (CSL Behring). Strong trauma and surgical bleeding protocols.
- Europe: Stable market (20% share, CAGR 6.5%). France (LFB), Switzerland (Octapharma). Established fibrinogen concentrate use.
- Rest of World: Latin America, Middle East. Smaller but growing.
8. Conclusion
The fibrinogen for injection market is positioned for strong growth through 2032, driven by trauma bleeding, postpartum hemorrhage, and surgical blood conservation. Stakeholders—from plasma fractionators to hospitals—should prioritize 1g vials for adult dosing, rapid reconstitution for emergency use, and goal-directed therapy protocols. By enabling plasma-derived coagulation protein replacement, fibrinogen for injection controls acute bleeding without volume overload.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
